Novartis sues J&J over "misleading" Tremfya data

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

Novartis (NVS +0.5%) has filed a lawsuit against Johnson & Johnson (JNJ +0.1%) unit Janssen over what it says is misleading data on psoriasis med Tremfya (guselkumab), a competitor to Novartis' Cosentyx (secukinumab).

The company claims that Janssen's presentations and marketing materials claim non-inferiority and superiority compared to Cosentyx but "cherry-pick" safety data, omitting the most serious treatment-related adverse events. It says it has sent three cease-and-desist letters to Janssen with no effect.

Subscribe for full text news in your inbox

This was corrected on 03/04/2019 at 11:33 AM. misleading Tremfya data